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Abstract
Endothelial arginase 1 was ablated to assess whether this prevents hyper-
glycemia-induced endothelial dysfunction by improving arginine availability
for nitric oxide production. Endothelial Arg1-deficient mice (Arg1-KOTie2)
were generated by crossing Arg1fl/fl (controls) with Tie2Cretg/ mice and ana-
lyzed by immunohistochemistry, measurements of hemodynamics, and wire
myography. Ablation was confirmed by immunohistochemistry. Mean arterial
blood pressure was similar in conscious male control and Arg1-KOTie2 mice.
Depletion of circulating arginine by intravenous infusion of arginase 1 or
inhibition of nitric oxide synthase activity with L-NG-nitro-arginine methyl
ester increased mean arterial pressure similarly in control (9  2 and
34  2 mmHg, respectively) and Arg1-KOTie2 mice (11  3 and
38  4 mmHg, respectively). Vasomotor responses were studied in isolated
saphenous arteries of 12- and 34-week-old Arg1-KOTie2 and control animals
by wire myography. Diabetes was induced in 10-week-old control and Arg1-
KOTie2 mice with streptozotocin, and vasomotor responses were studied
10 weeks later. Optimal arterial diameter, contractile responses to phenyle-
phrine, and relaxing responses to acetylcholine and sodium nitroprusside were
similar in normoglycemic control and Arg1-KOTie2 mice. The relaxing
response to acetylcholine was dependent on the availability of extracellular L-
arginine. In the diabetic mice, arterial relaxation responses to endothelium-
dependent hyperpolarization and to exogenous nitric oxide were impaired.
The data show that endothelial ablation of arginase 1 in mice does not mark-
edly modify smooth muscle and endothelial functions of a resistance artery
under normo- and hyperglycemic conditions.
Introduction
Vascular complications are the primary cause of morbid-
ity and mortality in diabetics. Endothelial dysfunction is
considered a critical factor in the development of these
complications (Luscher et al. 2003; Sena et al. 2013). One
aspect of endothelial dysfunction is a decrease in the
bioavailability of endothelium-derived nitric oxide
(EDNO). This decrease may be caused by lowered
endothelial nitric oxide synthase (NOS3) activity,
increased levels of endogenous NOS inhibitors, limited
availability of the NOS3 substrate arginine (Luscher et al.
2003; Cooke et al. 1991; Wu and Meininger 2000), or
increased scavenging of nitric oxide (NO) by reactive oxy-
gen species (ROS) (Gryglewski et al. 1986). Under
healthy, physiological conditions, sufficient L-arginine is
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available for NO production in the endothelium. How-
ever, this may be altered in pathological conditions, such
as diabetes, where arginine availability for NO synthesis
may be becoming limited. We previously showed that
under diabetic conditions arginine resynthesis from citrul-
line is necessary to maintain arginine supply for NO-
mediated arterial relaxation (Chennupati et al. 2014).
Arginine-resynthesizing enzymes (i.e., the enzymes of
the citrulline-NO cycle) and arginine-catabolizing
enzymes (arginases, ARG) tightly regulate intracellular
arginine concentrations (Li et al. 2001). The two arginase
isoforms, ARG1 and ARG2, have similar kinetic proper-
ties, but are encoded by separate genes. Both ARG1 and
ARG2 proteins were demonstrated in endothelium (for a
review, see Pernow and Jung (2013)) and implicated in
endothelial dysfunction. Increased Arg1 expression is asso-
ciated with endothelial dysfunction in diabetic patients
(Bagi et al. 2013; Beleznai et al. 2011) and mice (Romero
et al. 2012; Toque et al. 2013a).
To evaluate roles of arginases, three constitutive
knockout mouse models were previously developed:
Arg1/ (Iyer et al. 2002), Arg2/ (Shi et al. 2001), and
double knockout (KO) mice (Deignan et al. 2006).
Arg/ and double KO mice develop severe hyperam-
monemia and die within 10–14 days after birth (Iyer
et al. 2002). Intriguingly, heterozygous, constitutive par-
tial ablation of ARG1 (Arg1+/), complete deletion of
ARG2 (Arg2/), and the combination of these two
genotypes (Arg1+//Arg2/) partially rescue diabetes-
induced, endothelial dysfunction in mouse aorta and
corpus cavernosum (Romero et al. 2012; Toque et al.
2011). Because Arg1/ mice do not survive beyond
2 weeks after birth, the role of ARG1 in vascular dys-
function has not been investigated. We hypothesized that
limitation of the capacity of the endothelium to degrade
arginine via ARG1 improves arterial endothelium-depen-
dent relaxation, especially when NO-mediated relaxations
are compromised (as in diabetic mice). This question is
pertinent because ARG1 and NOS3 compete for the
same substrate. We tested this hypothesis in saphenous
arteries of normoglycemic and diabetic mice that did or
did not express ARG1 in their endothelium, because
these muscular resistance arteries are sensitive to impair-
ment of the NO-citrulline cycle (Chennupati et al.
2014).
Materials and Methods
Animals
All procedures were approved by the Committee for Ani-
mal Care and Use of Maastricht University (DEC 2008-
182 and 2012-027) and performed in accordance with
their guidelines. Endothelial ablation of ARG1 was
achieved by crossing Arg1fl/fl(Cloots et al. 2013) and Tie2-
Cretg/(Kisanuki et al. 2001) mice. Mice that lack ARG1
in their endothelium (Arg1fl/fl/Tie2Cretg/) are named
Arg1-KOTie2 hereafter. We have previously shown that
mice carrying the fully functional floxed alleles of the
ARG1 gene (Arg1fl/fl) are indistinguishable from their
wild-type littermates (Cloots et al. 2013). Therefore,
Arg1fl/fl/Tie2Cre/ littermates were used as control ani-
mals; 12- and 34-week-old male and female mice were
used. Mice were housed in standard cages (constant room
temperature and humidity, 12 h light/dark cycles) and
had free access to standard pelleted chow and tap water.
Diabetes was induced at the age of 10 weeks by
intraperitoneal (IP) injections of streptozotocin (STZ;
50 mgkg1) on 5 consecutive days (American diabetes
complications consortium AMDCC protocols; https://
www.diacomp.org). Blood glucose was measured follow-
ing overnight fasting at 1, 4, and 10 weeks following STZ
injections (Table S5), and male mice with stable blood
glucose concentration of ≥20 mmolL1 were used for the
experiments (mean  SEM: controls
22.8  0.8 mmolL1, n = 10 (Chennupati et al. 2014);
Arg1-KOTie2 23.1  0.6 mmolL1, n = 5). Female mice
were not included in the experiments because their fasting
blood glucose concentrations only transiently increased to
~60% of the values measured in males at 1 and 4 weeks
after STZ treatment and returned to pretreatment values
between 4 and 10 weeks (mean  SEM at 10 weeks: con-
trols 7.8  1.0 mmolL1, n = 8; Arg1-KOTie2
7.6  0.9 mmolL1, n = 4; Table S5; cf Chennupati
et al. 2014). This finding suggests that the b cells of
female mice are more resistant to STZ and regenerate
between 4 and 10 weeks after the treatment.
Solutions and drugs
Krebs-Ringer bicarbonate-buffered salt solution (KRB)
contained (in mmolL1): 118.5 NaCl, 4.7 KCl, 2.5 CaCl2,
1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, and 5.5 glucose.
The KRB solution was continuously aerated with 95%
O2/5% CO2 and maintained at 37°C. Indomethacin
(INDO; Sigma Aldrich, Zwijndrecht, NL) was dissolved in
ethanol. Acetylcholine (ACh), noradrenaline (NA),
phenylephrine (PHE), Nx-nitro-arginine methyl ester (L-
NAME), and sodium nitroprusside (SNP; all Sigma
Aldrich) were dissolved in KRB solution. High K+-KRB
solution was prepared by replacing 40 mmolL1 NaCl
with KCl. Buffers containing intermediate K+ concentra-
tions were prepared by mixing KRB and K+-KRB. In the
L-arginine-depletion experiment (Fig. 4), KRB was
replaced by L-arginine-free Iscove’s modified Dulbecco’s
medium.
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Plasma amino acid analysis
To determine plasma amino acids, blood was drawn from
the inferior vena cava using a heparinized syringe, cen-
trifuged, deproteinized by adding 50 lL plasma to tubes
containing 4 mg sulfosalicylic acid, and stored at 80°C.
Amino acid concentrations were determined by HPLC
(van Eijk et al. 1993).
Immunohistochemistry
Saphenous arteries were fixed in formaldehyde (4%) or
cold acetone/methanol/water (2:2:1; 4°C) overnight, dehy-
drated, and embedded in paraffin. Sections (4 lm) were
incubated overnight at 4°C with rabbit antibodies direc-
ted against ARG1 (1:10,000 in 10% normal goat serum
NGS; AMC, Amsterdam; de Jonge et al. 2002). Antibody
binding was visualized with alkaline phosphatase (AP)-
coupled goat anti-rabbit IgG antibodies (diluted 1:200 in
Teng-T/10% NGS: 100 mmolL1 Tris-HCl, pH 8.0,
50 mmolL1 EDTA, 1.5 mmolL1 NaCl, 2.5% (w/v)
gelatin, 0.5% (v/v) Tween 20, 10% (v/v) NGS) and
incubation with AP substrate (NBT/BCIP) for 15–90 min
at room temperature. Negative controls were incubated
with secondary antibody only. Background staining was
equalized by globally adapting the brightness of colors
with Adobe Photoshop, with panels C and G serving as
reference. The contrast was modified in the H&E-stained
panels E and H only.
Determination and manipulation of
hemodynamic parameters
We determined hemodynamic parameters in conscious,
unrestrained control, and Arg1-KOTie2 mice. Heparinized
indwelling polyethylene catheters were introduced into
the femoral artery and jugular vein under isoflurane anes-
thesia 2 days before the experiments (Janssen et al. 2000).
Analgesia was obtained by perioperative subcutaneous
injections of buprenorphine (0.03 mgkg1). On the day
of the experiment, the arterial line was connected to a
pressure transducer (Micro Switch 150 PC) and the signal
was sampled at 2.5 kHz. Mean arterial pressure (MAP)
and heart rate (HR) were derived from this signal using
the IDEEQ data acquisition system (Instrument Services,
Maastricht University, NL). The venous line was extended
outside the cage and filled with a 0.9% NaCl solution.
Hemodynamic parameters were allowed to stabilize before
pharmacological interventions. The following compounds
were applied via an intravenous catheter: 200 U purified
bovine ARG1 (Cell Sciences, Canton, MA, USA) dissolved
in 125 lL HEPES buffer (pH 7.4) or L-NAME
(10 mgkg1) dissolved in 0.9% saline. After the
experiments, animals were euthanized with 250 mgkg1
pentobarbital administered through the catheter. Cannu-
lation of femoral arteries in diabetic mice is associated
with a full occlusion of the main feeding artery of the leg.
In those mice, wound healing and revascularization are so
much impaired that the leg becomes necrotic. For this
reason, diabetic mice could not be subjected to the same
protocol as the nondiabetic mice.
Organ chamber experiments
Animals were euthanized by CO2/O2 inhalation. Saphe-
nous arteries were dissected free from perivascular adi-
pose tissue and mounted in a wire myograph (Danish
Myotechnology, Aarhus, DK). Arterial segments (2 mm)
were distended to the diameter at which maximal con-
tractile responses to 10 lmolL1 NA were obtained
(Chennupati et al. 2013; Hilgers et al. 2010). Optimal
diameters (Dopt) and maximal contractile responses to
NA are summarized in Table S2.
Contributions of NO, endothelium-
dependent hyperpolarization (EDH) and
cyclooxygenase products to endothelium-
dependent relaxation
Initially, a concentration-response curve (CRC) for PHE
(0.01–10 lmolL1) was recorded. Following the contrac-
tion induced by 10 lmolL1 PHE, an ACh CRC (0.01–
10 lmolL1) was generated. Next, arteries were con-
tracted using K+ (40 mmolL1), and again an ACh CRC
(0.01–10 lmolL1) was recorded. These experiments
were repeated in the presence of the cyclooxygenase inhi-
bitor INDO (10 lmolL1) and in the presence of both
INDO and the NOS inhibitor L-NAME (100 lmolL1)
to assess the contribution of NO to arterial relaxation
(Morikawa et al. 2005; Matoba et al. 2000).
Sensitivity of vascular smooth muscle to NO
During contraction of the saphenous arteries with PHE
(10 lmolL1) in the presence of INDO (10 lmolL1)
and L-NAME (100 lmolL1), the relaxing effects of the
NO-donor SNP (0.01–10 lmolL1) were recorded.
Statistical analysis
All CRCs for contractile stimuli are expressed as percentage
of the maximal response to 10 lmolL1 NA prior to the
administration of pharmacological inhibitors. Relaxing
responses were expressed as percentage reduction of the
level of contraction. Individual CRCs were fitted to a non-
linear sigmoid regression curve (Graphpad Prism 5.0).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Sensitivity, maximal effect (Maximal response), and amino
acid concentrations are shown as means  SEM. Two-way
ANOVA followed by a Bonferroni post hoc test was used to
compare multiple groups. Group statistics for hemody-
namic parameters were analyzed by an independent sam-
ples test to determine differences between genotypes,
followed by paired t-tests to assess the effects of treatments.
Results
Ablation of ARG1 protein from endothelial
cells
Endothelial ablation of ARG1 was achieved by crossing
Arg1fl/fl and Tie2Cretg/ mice. Mice that lack ARG1 in
their endothelium (Arg1fl/fl/Tie2Cretg/) are named Arg1-
KOTie2 hereafter. We have previously shown that mice
carrying the fully functional floxed alleles of the ARG1
gene (Arg1fl/fl) are indistinguishable from their wild-type
littermates (Cloots et al. 2013). Therefore, Arg1fl/fl/
Tie2Cre/ littermates were used as control animals. To
verify endothelial deletion of ARG1 protein, saphenous
artery sections were stained for ARG1. The sensitivity of
immunohistochemical staining for ARG1 in endothelial
cells was much improved by fixation of the tissues in ace-
tone/methanol/water (2:2:1) instead of formaldehyde. In
young adult control mice, endothelial ARG1 was weakly
expressed (Fig. 1A and E). In line with earlier observa-
tions (Romero et al. 2012; Toque et al. 2013a; White
et al. 2006; Pernow et al. 2015), we observed stronger
expression of ARG1 in arteries of 34-week-old control
(Fig. 1B and F) and 22-week-old diabetic mice (Fig. 1C
and G), but not in diabetic Arg1-KOTie2 mice (Fig. 1D
and H). Specificity of the antibody-staining procedure
was demonstrated by zonated ARG1 expression in liver
sections (Fig. S1) (Dingemanse et al. 1996).
Plasma amino acid concentrations in control
and Arg1-KOTie2 mice
Especially in diabetes, upregulation of arginase expression
can limit the availability of arginine for NOS in aging ves-
sels (Romero et al. 2012; Toque et al. 2013a; Pernow
et al. 2015; Santhanam et al. 2008). Thus, absence of
endothelial ARG1 might improve endothelial function by
increasing arginine availability for NOS3 in diabetic mice.
We only studied male diabetic mice, because the AMDCC
protocol induced only transient hyperglycemia in female
C57BL/6 mice (see M&M section). Plasma arginine con-
centrations were similar in control and Arg1-KOTie2 mice
(Tables 1 and S1). Despite increased ARG1 expression in
the endothelium of diabetic control mice, their plasma
arginine concentration was comparable to that of
normoglycemic control mice. In diabetic Arg1-KOTie2
mice, however, the plasma arginine concentration was
increased (~30%; P = 0.030). The concentration of the
arginine precursor citrulline was increased in diabetic
mice compared with normoglycemic mice, while that of
tryptophan was significantly decreased in diabetic Arg1-
KOTie2 mice, and a trend (P = 0.054) toward a decrease
was observed in diabetic control mice (Tables 1 and S1).
Hemodynamic parameters in male control
and Arg1-KOTie2 mice
To assess the effects of endothelial Arg1 ablation on
hemodynamics, mean arterial pressure (MAP) and heart
rate (HR) were recorded in conscious male mice. Basal
MAP did not differ between conscious unrestrained con-
trol and Arg1-KOTie2 mice (P = 0.777). MAP after argi-
nase infusion did not differ between control and Arg1-
KOTie2 mice (P = 0.257), demonstrating that endothelial
Arg1 ablation does not influence the hemodynamic effects
of circulating arginine. Accordingly, data from both
groups were pooled. The effects of circulating arginine on
blood pressure maintenance were assessed by a bolus
injection of 200U ARG1, which rapidly decreases the con-
centration of circulating arginine to ~13% of the original
plasma concentration during at least 20 min (Chennupati
et al. 2014; Wijnands et al. 2015). This intervention
resulted in a small but significant rise of MAP to 108% of
control values (9  2.5 mmHg increase, P = 0.007;
Fig. 2). Again, control and Arg1-KOTie2 mice did not dif-
fer significantly (P = 0.115). To compare the effects of
arginine depletion to those of NOS inhibition, the same
animals received a bolus injection of the NOS inhibitor
L-NAME (10 mgkg1) 24 h later. This treatment resulted
in a 36  2 mmHg increase in MAP (P < 0.000), that is,
in a fourfold higher increase than that caused by plasma
arginine depletion. No significant differences were
observed between knockout and wild-type animals.
Basal HR did not differ between control
(651  21 beats/min, n = 6) and Arg1-KOTie2 mice
(713  42 beats/min, n = 6, P = 0.186, Table 2). The
decrease in circulating arginine concentration upon injec-
tion of 200U ARG1 (previous paragraph) had no significant
effect on HR and again, and no difference between geno-
types was observed. Accordingly, data of control and Arg1-
KOTie2 animals were pooled (Table 2). HR decreased to a
similar extent in L-NAME-treated control and Arg1-KOTie2
mice (189  46/min, n = 7, P = 0.006).
Reactivity of isolated saphenous arteries
Endothelial ARG1 deficiency might entail compensatory
mechanisms such as increased arterial contractility or
2018 | Vol. 6 | Iss. 11 | e13717
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decreased vasodilator responses to maintain blood pres-
sure. We, therefore, studied the effects of endothelial
Arg1 ablation on vasomotor responses in more detail in
saphenous arteries isolated from male and female mice of
12- and 34-week-old control and Arg1-KOTie2 mice, and
22-week-old male STZ-treated mice of both genotypes.
Contractile responses of control and Arg1-KOTie2
arteries
The maximal contractile response to 10 lmolL1 nora-
drenaline (NA) was comparable in 12- and 34-week-
old male and female control and Arg1-KOTie2 mice
(Tables S2 (male); S5 (female mice). The sensitivity
and maximal contractile response to phenylephrine
(PHE) (0.01–10 lmolL1) or K+ (40 mmolL1) in the
absence and presence of L-NAME (100 lmolL-1) or
indomethacin (cyclooxygenase inhibitor, INDO;
10 lmolL-1) and a combination of the former did also
not differ significantly between groups (Tables S2, S5).
Contractile responses did not differ significantly
between saphenous arteries from male diabetic Arg1-
KOTie2 and control mice (Table S2), showing that a
decreased capacity for endothelial arginine degradation
does not improve contractile responses of vessels in
diabetic mice.
Acetylcholine (ACh)-induced relaxations during
PHE-induced contractions
ACh-induced relaxations were studied during PHE-
induced contractions. In the absence of pharmacological
inhibitors and in the presence of INDO, the maximal
response and sensitivity to ACh were similar in control
and Arg1-KOTie2 mice of both sexes and both age groups
(Fig. 3A and D male mice and S2 female mice, Tables 3,
S3, S4, S5). INDO had no statistically significant effects
on ACh-relaxation irrespective of genotype or age
(Fig. 3A, B, D and E). The combination of INDO and L-
LAME reduced ACh-induced relaxations to a similar
degree in all groups of nondiabetic arteries (Fig. 3B, C, E
and F). Thus, in control arteries, the presence or absence
of endothelial ARG1 does not affect endothelium-depen-
dent relaxation. As shown earlier in mesenteric arteries
(Morikawa et al. 2005), diabetes reduced the relaxation
responses in saphenous arteries (Fig. 3G, H and I). How-
ever, the maximal response and sensitivity of ACh-
induced relaxations did not differ between diabetic con-
trol and diabetic Arg1-KOTie2 mice in any of conditions
tested (Fig. 3G, H and I).
In view of the above-described lack of an effect of
genotype on ACh-induced arterial relaxations, we studied
whether the extracellular L-arginine concentration can be
A B C D
E F G H
Figure 1. Expression of ARG1 protein in saphenous arteries of male mice. Panel (A): control, panel (B): 8-month-old normoglycemic control,
panel (C): diabetic control (DM), panel (D): diabetic Arg1-KOTie2 mice. Panels (E, F, G) and (H) show the complementary H&E staining of a serial
section of the respective arteries. Arrows indicate endothelial cells. All tissues were fixed with acetone/methanol/water (see Materials and
Methods).
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limiting for these relaxations in control mice. We, there-
fore, subjected isolated arteries in L-Arg-free Iscove’s
modified Dulbecco’s medium to 14 consecutive contrac-
tion-relaxation cycles at 20-min intervals. Figure 4A
shows that the sensitivity and maximal response to ACh
progressively decreased. To demonstrate that this was due
to L-arginine depletion, we repeated the experiment and
added L-arginine to the culture medium after the last
contraction-relaxation cycle (Fig. 4B). Partial restoration
of the relaxing response to ACh demonstrates that the
decline of the relaxing response indeed resulted from L-
Arg depletion.
Endothelium-derived NO
Endothelium-derived NO (EDNO) contributes to
endothelium-dependent relaxation of muscular resistance
arteries (Chennupati et al. 2013). To test for differences
in EDNO release, we inhibited endothelium-dependent
hyperpolarization (EDH) by depolarizing the vessels with
high potassium buffer (40 mmolL1 K+) and by inhibit-
ing cyclooxygenases using INDO (Chennupati et al.
2013). Under these conditions, relaxing responses to ACh
can entirely be attributed to NO (Chennupati et al.
Table 1. Effect of Arg1 ablation on plasma amino acid concentrations in 12-week-old healthy male and 22-week-old male diabetic mice.
Plasma amino acids [lmolL] Control Arg1-KOTie2 Control STZ-treated Arg1-KOTie2 STZ-treated
Alanine 484  25 390  72 500  51 575  67
Arginine 103  13 126  26 121  9 156  81
Asparagine 46  15 33  11 39  5 61  13
Ornithine 91  4 79  8 100  9 116  15
Citrulline 52  5 46  4 78  52 85  72
Glutamic acid 88  9 80  15 97  10 110  14
Glutamine 518  80 518  102 537  29 577  55
Glycine 276  16 260  35 236  13 275  26
Histidine 71  5 61  5 56  5 59  4
Isoleucine 97  10 87  8 170  21 192  42
Leucine 159  11 154  14 279  36 313  68
Lysine 256  20 256  32 336  67 485  78
Methionine 43  1 40  4 37  4 48  5
Phenylalanine 43  10 59  5 59  3 72  7
Taurine 72  11 73  12 80  6 131  152,1
Serine 132  16 115  17 129  11 149  21
Threonine 132  17 116  15 140  13 169  21
Tryptophan 259  21 255  33 169  19 159  162
Tyrosine 332  31 404  43 312  38 306  27
Valine 259  15 220  13 387  49 432  90
ΣAA 3578  256 3449  407 3863  215 4851  554
Arginine-availability index 0.33  0.03 0.32  0.02 0.36  0.05 0.26  0.03
All values are shown as means  SEM.
1P < 0.05 compared with the corresponding control group (knockout vs. wild type).
2P < 0.05 compared with the corresponding healthy group (diabetes vs. healthy). Control: n = 3; Arg1-KOTie2: n = 4; STZ-control: n = 14;
STZ-Arg1-KOTie2: n = 6. Arginine-availability index: [Arg]/([Orn] + [Lys]). For P-values of the comparisons, see Table S1.
Figure 2. Effects of endothelial Arg1 ablation on mean arterial
blood pressure (MAP) in 34-week-old conscious male mice. Blood
pressure was measured in the same mice 2 (Basal, +Arginase) and
3 days (Basal 2, +L-NAME) after implantation of a femoral artery
catheter connected to a pressure transducer. Since MAP in control
and Arg1-KOTie2 mice did not differ either under basal or treatment
conditions, data from both groups were pooled. Left side: MAP
under basal conditions and after a bolus injection of 200U bovine
ARG1 via a jugular vein catheter. Right side: MAP under basal
conditions one day later (Basal 2) and after intravenous L-NAME
(10 mgkg1) injection (right). Values are means  SEM. Nine mice
(five control + four Arg1-KOTie2) received the arginase infusion; due
to loss of catheter patency in one control mouse, eight mice
received the L-NAME infusion. Differences between treatments
were analyzed with a paired t-test.
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Table 2. Effects of genotype, arginase 1, and L-NAME treatment on heart rate in conscious male mice.
Comparison of genotypes Effect of treatment
Control [beats. min1] ARG1-KOTie2 [beats. min1] P DHR [bp. min1] P
Basal HR 651  21 713  42 0.184
Before ARG1 657  37 733  45 0.230 ARG1 39  33 0.276
After ARG1 627  35 693  49 0.326
Before L-Name 661  30 768  48 0.109 L-NAME 189  46 0.006
After L-NAME 525  15 531  66 0.914
Heart rate was determined as described in Materials and Methods. Values are given as means  SEM. Differences between genotypes were
assessed with an independent t-test (n per group 3–5 animals). Since control and Arg1-KOTie2 mice did not differ significantly under any of
the conditions tested, all animals were pooled to assess the effect of the treatments with a paired t-test (n for ARG1 = 9, L-NAME = 7).
Figure 3. Effects of endothelial Arg1 ablation on relaxation responses to ACh (0.01–10 lmolL1) during PHE- (10 lmolL1) induced
contractions in saphenous arteries isolated from 12- (panels A–C) or 34- (panels D–F) week-old normoglycemic and 22-week-old hyperglycemic
(panels G–I) male mice. Black squares: control mice; white circles: Arg1-KOTie2 mice. Panels (A, D, G) in the absence of pharmacological
inhibitors. Panels (B, E, H) in the presence of indomethacin (INDO, 10 lmol.L1). Panels (C, F, I) in the presence of INDO (10 lmolL1) and L-
NAME (100 lmolL1). Values are shown as means  SEM (n = 5–7; for the number of animals per individual experiment, see Table S2).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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2013). These responses were comparable in all groups of
mice (Fig. S2; Tables 3 and S3).
Relaxing responses to SNP
To study that the genetic modification did not affect
responses of vascular smooth muscle cells to exogenous
NO relaxations in response to the NO-donor sodium
nitroprusside (SNP; 0.01–10 lmolL1) were studied dur-
ing PHE-induced contractions in the presence of INDO
and L-NAME. Sensitivity and maximal response to SNP
were comparable between control and Arg1-KOTie2 mice
of both age groups and sexes (Fig. 5, Tables 3, S3 and
S4). However, hyperglycemia resulted in a reduced
Table 3. Effect of endothelial ablation of Arg1 on relaxation responses.
Control Arg1-KOTie2
Sensitivity Maximal response% n Sensitivity Maximal response% n
12-week-old mice
Without inhibitors 6.7  0.1 94  2 7 6.7  0.1 97  3 4
INDO 6.5  0.2 94  1 6 6.6  0.1 88  4 5
INDO + L-NAME 6.0  0.1 56  7 7 6.2  0.2 57  12 5
Relaxation to EDNO 6.1  0.1 60  4 6 5.9  0.1 56  6 4
Relaxation to SNP 7.6  0.1 97  1 5 7.7  0.1 97  1 5
34-week-old mice
Without inhibitors 6.7  0.1 90  3 7 6.6  0.1 88  6 4
INDO 6.6  0.1 88  3 8 6.7  0.3 89  6 4
INDO + L-NAME NA 39  6 7 NA 29  8 4
Relaxation to EDNO 6.1  0.2 54  7 6 5.8  0.2 53  6 4
Relaxation to SNP 7.5  0.1 97  1 7 7.6  0.3 98  1 5
22-week-old diabetic mice
Without inhibitors 6.5  0.1 86  6 7 6.4  0.2 82  8 5
INDO 6.5  0.1 81  4 8 6.5  0.2 76  7 5
INDO + L-NAME NA 18  5 7 NA 19  6 5
Relaxation to EDNO 6.2  0.1 47  3 6 6.0  0.2 41  6 5
Relaxation to SNP 7.0  0.12 98  1 7 6.8  0.11,2 96  1 5
Relaxation responses to acetylcholine (ACh; 0.01–10 lmolL1) in PHE- (10 lmolL1) or K+ (40 mmolL1) contracted vessels were determined
in the presence or absence of indomethacin (INDO, 10 lmolL1) and L-NAME (100 lmolL1). Maximal relaxation (Maximal response) is
expressed as % reduction of the maximal contractile response to PHE (10 lmolL1), except for endothelium-derived nitric oxide (EDNO)
responses (% reduction of maximal contractile response to 40 mmolL1 K+). In the presence of NOS inhibitor L-NAME (100 lmolL1) and
INDO (10 lmolL1), the maximal relaxation to an NO-donor is determined by exposing the vessels to SNP (0.01–10 lmolL1).
1P < 0.05 compared with the corresponding control group (knockout vs. wild type).
2P < 0.05 compared with the corresponding control group (diabetes vs. control). All values are shown as mean  SEM.
Figure 4. The effect of 14 consecutive contraction-relaxation cycles (CRC) on ACh-induced relaxation during contractions induced by PHE
(10 lmolL1). Two-mm arterial segments were kept in L-Arg-free culture medium during the experiment. The EC50 increased, whereas the
Maximal response decreased with increasing number of CRCs (panel A). In a separate experiment (panel B), the arterial segments were
subjected to repeated CRCs in L-Arg-free culture medium until relaxation had decreased to ~25%. L-Arg (1 mmolL1) was then added. ACh-
induced relaxations were tested after 60 min. CRC: contraction-relaxation cycle.
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sensitivity (sensitivity: 7.0  0.1) to SNP compared with
12- and 34-week-old normoglycemic control mice (sensi-
tivity: 7.6  0.1 and 7.5  0.1, respectively; Fig. 5,
Tables 2 and S3), as was described earlier (Csanyi et al.
2007). Ablation of endothelial arginase 1 (Arg1-KOTie2)
further reduced arterial smooth muscle sensitivity to SNP
(P = 0.045; Fig. 5C, Tables 3 and S3).
Discussion
In this study, we tested the hypothesis that endothelial
ablation of the Arg1 gene increases endothelium-depen-
dent vasodilatation in muscular resistance arteries of con-
trol and diabetic mice. The major findings of this study
are that (1) diabetic Arg1-KOTie2 mice have a higher argi-
nine concentration in plasma, (2) hemodynamics are not
affected by endothelial ARG1 ablation, (3) vasomotor
function is not affected by endothelial ARG1 deficiency in
normoglycemic mice, and (4) diabetes-induced alterations
in arterial smooth muscle reactivity and endothelium-
dependent relaxations are not prevented by endothelial
ARG1 ablation.
In this study, we used the Tie2-Cre transgene (Kisanuki
et al. 2001) to eliminate floxed Arg1 from the endothelium.
This transgene has an excellent reputation in eliminating
floxed DNA sequences (Kisanuki et al. 2001, 2010; Hamada
et al. 2005; Koni et al. 2001; Schlaeger et al. 2005) and,
accordingly, was also effective in eliminating floxed Ass
from the endothelium of the saphenous arteries in C57BL/6
mice (Chennupati et al. 2014). That study showed that
resynthesis of arginine from citrulline was necessary to pro-
vide sufficient arginine for NO synthesis in saphenous
arteries of diabetic mice (Chennupati et al. 2014). Further-
more, we showed earlier that lipopolysaccharide-treated
Arg1-KOTie2 mice produced more NO in the endothelium
of their carotid arteries and jejunum than control
mice (Wijnands et al. 2014). In addition, Arg1-KOTie2 mice
suffering from allergic asthma did not express ARG1
mRNA or protein in their lungs, even though this condi-
tion upregulates Arg1 expression >200-fold in control
mice (Cloots et al. 2013). These data underscore our
claim that Arg1 expression was eliminated from the
endothelium.
The Tie2-Cre transgene is best known for its expression
in cells of hematopoietic origin, such as endothelial cells
and macrophages (Tang et al. 2010). Thus, in our Arg1-
KOTie2 mice, cells derived from the hematopoietic lineage
are also devoid of ARG1, and this may have effects on
circulating concentrations of citrulline and arginine.
Therefore, a contribution of Arg1 elimination in macro-
phages and/or erythrocytes to blood pressure responses
cannot be ruled out. In fact, in a previous study with
these mice, we observed effects of Arg1 ablation that
could be attributed to either macrophages (cytokine pro-
duction) or endothelium (NOS-dependent effects on the
mucosal perfusion of villi in the jejunum) (Wijnands
et al. 2014). However, it is highly unlikely that substantial
numbers of erythrocytes and macrophages were present
in the walls of the vessels used in the wire-myograph
measurements. Ablation of Arg1 in cells of the myeloid
lineage has been shown to increase TH2-mediated inflam-
matory responses in mouse models of schistosoma infec-
tion (Pesce et al. 2009). It is, therefore, possible that
potential beneficial effects of endothelial Arg1 ablation are
masked by increased vascular inflammation due to Arg1
ablation in cells of the myeloid lineage in those same
mice, even though we did not find histological evidence
of increased vascular inflammation in the vessel walls and
Figure 5. The effect of endothelial Arg1 ablation on relaxation responses to sodium nitroprusside (SNP, 0.01–10 lmolL1) during PHE-
(10 lmolL1) induced contraction in saphenous arteries of 12- (panel A), 34- (panel B) week-old normoglycemic and 22-week-old diabetic
(panel C) male mice. Black squares: control mice; white circles: Arg1-KOTie2. All experiments were performed in the presence of INDO
(10 lmolL1) and L-NAME (100 lmolL1). Values are shown as means  SEM (n = 5–7; for the number of animals per individual experiment,
see Table S2).
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surrounding tissue. In a model of allergic asthma in the
same mouse strain, we did not find an effect of Arg1
ablation on pulmonary inflammation as determined by
cytokine expression and histology (Cloots et al. 2013).
We did, however, not investigate cytokine profiles, NO
production or leukocyte adhesion to vessel walls in the
current model and can, therefore, not exclude that some
vascular inflammation was present that could have
masked potential beneficial effects of endothelial Arg1
ablation.
A limitation of our genetic approach to eliminate Arg1
expression is that it may not be possible to selectively
manipulate endothelial arginine concentrations in resis-
tance arteries. In many vascular beds, resistance arteries
exhibit heterocellular myoendothelial gap junctions (Dora
et al. 2003; Sandow et al. 2012; Hilgers and De Mey
2009) through which arginine could diffuse from the
smooth muscle to the endothelial cells and vice versa.
Arginine diffusion through these pores may compensate
for changes in endothelial arginine concentration elicited
by, for example, decreased arginine degradation in
endothelial cells. In endothelial cells, gap junctions are
primarily formed of the connexin proteins CX37 (GJA4),
CX40 (GJA5) and CX43 (GJA1) (Meens et al. 2015).
Because the diabetic condition reduces their expression in
vascular walls (Bobbie et al. 2010; Hou et al. 2008),
reduced gap-junction activity could explain limited reple-
tion of arginine in this condition (Chennupati et al.
2014). This hypothesis implies that the myoendothelial
gap junction-dependent repletion of endothelial arginine
is not sufficiently reduced to limit NOS activity irrespec-
tive of whether or not ARG1 is present in the endothe-
lium. Unfortunately, this hypothesis is difficult to test,
since inhibitors of gap-junction activity are well known to
be nonselective (Matchkov et al. 2004). The alternative
genetic approach is also complex, since it would require
the production of an endothelium-specific triple knockout
of C 9 37, C 9 40, and C 9 43.
Both ARG1 and ARG2 are found in endothelium (Per-
now and Jung 2013) and have been implicated in
endothelial dysfunction. Toque et al. (Toque et al. 2013b)
attributed a larger role to ARG1 than ARG2 in mediating
hypertension. ARG1 also appears involved in diabetes as
underscored in our study by the increased endothelial
ARG1 staining in diabetic control mice and increased
plasma arginine concentration in diabetic Arg1-KOTie2
mice.
One would assume that elimination of ARG1 should
increase the circulating arginine concentration. However,
in this study, such increase was only observed in diabetic
Arg1-KOTie2 mice. The similar 30% increase in the
summed concentration of amino acids suggests that
the effect is not specific for arginine. In agreement, the
arginine-availability index (plasma [Arg]/([Orn]+[Lys]))
did not change (Table 1). This index is a marker for the
competitive strength of arginine over other basic amino
acids for transport into endothelial cells (Morris et al.
2004). When plasma arginine was depleted acutely by
ARG1 bolus injection, the arginine-availability index
dropped to ~25% of the original (Wijnands et al. 2015).
In the present study, a similar intervention caused blood
pressure to increase (Fig. 3A), implying that extracellular
arginine availability had become limiting for blood pres-
sure maintenance. However, even during this challenge,
the increase in blood pressure was only ~30% of that
achieved by inhibition of NOS by L-NAME, implying an
important role for intra-endothelial arginine repletion or
resynthesis by argininosuccinate synthase (ASS). This con-
clusion is underscored by our earlier findings in diabetic
Ass-KOTie2 mice; the summed amino acid concentrations
and the arginine-availability index were similar to con-
trols (Chennupati et al. 2014) as in this study. Whereas
no endothelial dysfunction developed in control Ass-
KOTie2 mice, it did in diabetic Ass-KOTie2 mice, showing
that the contribution of resynthesis of arginine via ASS
to NO synthesis became a limiting factor in diabetes
(Chennupati et al. 2014). In the jejunum of untreated
Arg1-KOTie2 mice, on the other hand, NOS3 was hypo-
phosphorylated on Thr495 and tended to be hyper-phos-
phorylated on Ser1177 (Wijnands et al. 2014), suggesting
that Arg1 deficiency indeed increased NOS3 activity
(Chen et al. 2008; Lin et al. 2003). In fact, we based our
hypothesis that a limitation of the capacity of the
endothelium to degrade arginine via ARG1 would
improve arterial endothelium-dependent relaxation. The
combination of our earlier finding that the diabetic con-
dition does limit the ASS-mediated repletion of arginine
and finding in the present study that endothelial Arg1
elimination does not improve direct smooth muscle relax-
ation in (hyperglycemic) saphenous arteries implies that,
although the endothelial arginine pool cannot be suffi-
ciently repleted by surrounding smooth muscle cells, this
pool is not sufficiently reduced to limit NOS activity in
diabetic Arg1-KOTie2 mice.
EDH-related arterial relaxing responses were reduced in
diabetic mice, as shown earlier (Chennupati et al. 2014;
Morikawa et al. 2005),. In mouse mesenteric arteries,
endothelium-derived H2O2 mediates these responses
(Matoba et al. 2000). The main sources of H2O2 are
superoxide dismutases (SODs) (Morikawa et al. 2003).
The superoxide anion substrates of these SODs can be
generated by a broad variety of enzymes such as the mito-
chondrial electron transfer chain, NADPH oxidases, xan-
thine oxidase, cyclooxygenases, lipoxygenase, and NO
synthases (Fleming et al. 2001; Katusic 1996; Stroes et al.
1998). Superoxide anion production by NOS (EDH/H2O2
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production by the endothelium) is markedly enhanced by
“uncoupling” and de-dimerization of the enzyme in
response to shortage the co-factor BH4 or the substrate
(L-Arg) (Munzel et al. 2005; Forstermann and Munzel
2006). Although we did not investigate the underlying
mechanism for reduced EDH responses in mouse saphe-
nous arteries during diabetes, substrate availability can be
one of the factors. Accordingly, we expected that EDH-
dependent relaxation responses in Arg1-KOTie2 mice
would be reduced. However, this was not observed. Other
factors in superoxide/H2O2 generation may have con-
tributed.
Diabetic mice displayed reduced smooth muscle
sensitivity to exogenous NO. Despite comparable
overall endothelium-dependent relaxation, this was
more pronounced in Arg1-KOTie2 than control mice.
This may indicate increased EDNO production in
Arg1-KOTie2 mice, which would be in line with our
initial hypothesis that substrate abundance in
endothelial cells increases NO production. Over time,
this could have been compensated by a progressively
reduced sensitivity of the arterial smooth muscle cells
to NO.
In conclusion, deletion of Arg1 using the Tie2 pro-
moter did not affect MAP or heart rate in control mice.
In addition, ex vivo studies of saphenous arteries from
control and diabetic mice showed that arterial smooth
muscle and endothelium-dependent relaxing responses
were largely unaffected by ablation of Arg1 in the
endothelium and hematopoietic cells. Comparison of the
responses of endothelial Ass (our previous study) and
Arg1 ablation may suggest that only ASS-generated argi-
nine is accessible to NOS3 in this model (Flam et al.
2001).
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Table S1. Fasting blood glucose concentrations in male
and female control and Arg1-KOTie2 mice before (basal
value) and at the indicated times after streptozotocin
treatment. All values are shown as means  SEM.
Table S2. Effect of Arg1-ablation on saphenous artery
(SA) diameter and SA contractile responses in male mice.
Emax values are expressed as % of the maximal response
to noradrenaline (10 µmolL1 NA).
Table S3. P-values of comparisons of plasma amino acid
concentrations between control and Arg1-KOTie2 mice,
and normoglycemic and diabetic mice, respectively.
Table S4. P-values of comparisons of relaxation responses
as shown in Table 2.
Table S5. Effect of Arg1-ablation on saphenous artery
(SA) diameter, contractile, and relaxation responses in
female mice.
Figure S1. Specificity of arginase-1 antibody was demon-
strated by simultaneous staining of liver tissue.
Figure S2. The effect of endothelial Arg1 ablation on
relaxation responses to ACh (0.01–10 µmolL–1) during
K+- (40 mmolL–1) induced contractions in saphenous
arteries of 12- (panel A), 34- (panel B) week-old normo-
glycemic and 22-week-old diabetic (panel C) male mice.
Black squares: control mice; white circles: Arg1-KOTie2
mice.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 11 | e13717
Page 13
R. Chennupati et al. Arginase 1 in Endothelial Function
